marijuana stock news

Cara Therapeutics to Webcast Presentation at 14th Annual Needham Healthcare Conference

SHELTON, Conn., April 7, 2015 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the 14th Annual Needham Healthcare Conference on Tuesday, April 14, 2015, at 3:00 p.m. ET in New York City.

A live webcast of the presentation can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body’s peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

Contact:
INVESTOR CONTACT:
Jesse Baumgartner
Stern Investor Relations, Inc.
212-362-1200
Jesse@sternir.com
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Ascend Wellness Holdings, Inc. (AAWH) Announces Participation in Upcoming Conferences and Events

Ascend Wellness Holdings Announces Participation in Upcoming Conferences and Events Ascend Wellness…

GT BIOPHARMA, INC. ANNOUNCES ADDITIONAL POSITIVE DATA FROM ITS PHASE 1 CLINICAL TRIAL FOR MYASTHENIA GRAVIS AND POTENTIAL FOR ACCELERATION OF THE START OF ITS PHASE 2 TRIAL

WASHINGTON, DC / MARCH 26, 2018 / GT Biopharma Inc. (OTCQB “GTBP”…

$AGSTF Announces Creation of Cannabis Advisory Board

Future Farm Announces Creation of Cannabis Advisory Board Appoints Expert Cultivator Chris…

Reliq Health Technologies Inc. (RQHTF) Announces Six New Primary Care Physicians in Texas

Reliq Health Technologies Announces Six New Primary Care Physicians in Texas to…